Lipid nanoparticle encapsulated nucleoside-modified mRNA vaccines elicit polyfunctional HIV-1 antibodies comparable to proteins in nonhuman primates
Development of an effective AIDS vaccine remains a challenge. Nucleoside-modified mRNAs formulated in lipid nanoparticles (mRNA-LNP) have proved to be a potent mode of immunization against infectious diseases in preclinical studies, and are being tested for SARS-CoV-2 in humans. A critical question is how mRNA-LNP vaccine immunogenicity compares to that of traditional adjuvanted protein vaccines in primates. Here, we found that mRNA-LNP immunization compared to protein immunization elicited either the same or superior magnitude and breadth of HIV-1 Env-specific polyfunctional antibodies. Immunization with mRNA-LNP encoding Zika premembrane and envelope (prM-E) or HIV-1 Env gp160 induced durable neutralizing antibodies for at least 41 weeks. Doses of mRNA-LNP as low as 5 μg were immunogenic in macaques. Thus, mRNA-LNP can be used to rapidly generate single or multi-component vaccines, such as sequential vaccines needed to protect against HIV-1 infection. Such vaccines would be as or more immunogenic than adjuvanted recombinant protein vaccines in primates.
| Errataetall: | |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2020 |
|---|---|
| Enthalten in: |
bioRxiv : the preprint server for biology - (2020) vom: 31. Dez. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Saunders, Kevin O [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 23.04.2022 published: Electronic UpdateIn: NPJ Vaccines. 2021 Apr 9;6(1):50. - PMID 33837212 Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1101/2020.12.30.424745 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM319621995 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM319621995 | ||
| 003 | DE-627 | ||
| 005 | 20231225171836.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2020.12.30.424745 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1065.xml |
| 035 | |a (DE-627)NLM319621995 | ||
| 035 | |a (NLM)33398289 | ||
| 035 | |a (PII)2020.12.30.424745 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Saunders, Kevin O |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Lipid nanoparticle encapsulated nucleoside-modified mRNA vaccines elicit polyfunctional HIV-1 antibodies comparable to proteins in nonhuman primates |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 23.04.2022 | ||
| 500 | |a published: Electronic | ||
| 500 | |a UpdateIn: NPJ Vaccines. 2021 Apr 9;6(1):50. - PMID 33837212 | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Development of an effective AIDS vaccine remains a challenge. Nucleoside-modified mRNAs formulated in lipid nanoparticles (mRNA-LNP) have proved to be a potent mode of immunization against infectious diseases in preclinical studies, and are being tested for SARS-CoV-2 in humans. A critical question is how mRNA-LNP vaccine immunogenicity compares to that of traditional adjuvanted protein vaccines in primates. Here, we found that mRNA-LNP immunization compared to protein immunization elicited either the same or superior magnitude and breadth of HIV-1 Env-specific polyfunctional antibodies. Immunization with mRNA-LNP encoding Zika premembrane and envelope (prM-E) or HIV-1 Env gp160 induced durable neutralizing antibodies for at least 41 weeks. Doses of mRNA-LNP as low as 5 μg were immunogenic in macaques. Thus, mRNA-LNP can be used to rapidly generate single or multi-component vaccines, such as sequential vaccines needed to protect against HIV-1 infection. Such vaccines would be as or more immunogenic than adjuvanted recombinant protein vaccines in primates | ||
| 650 | 4 | |a Preprint | |
| 700 | 1 | |a Pardi, Norbert |e verfasserin |4 aut | |
| 700 | 1 | |a Parks, Robert |e verfasserin |4 aut | |
| 700 | 1 | |a Santra, Sampa |e verfasserin |4 aut | |
| 700 | 1 | |a Mu, Zekun |e verfasserin |4 aut | |
| 700 | 1 | |a Sutherland, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Scearce, Richard |e verfasserin |4 aut | |
| 700 | 1 | |a Barr, Maggie |e verfasserin |4 aut | |
| 700 | 1 | |a Eaton, Amanda |e verfasserin |4 aut | |
| 700 | 1 | |a Hernandez, Giovanna |e verfasserin |4 aut | |
| 700 | 1 | |a Goodman, Derrick |e verfasserin |4 aut | |
| 700 | 1 | |a Hogan, Michael J |e verfasserin |4 aut | |
| 700 | 1 | |a Tombacz, Istvan |e verfasserin |4 aut | |
| 700 | 1 | |a Gordon, David N |e verfasserin |4 aut | |
| 700 | 1 | |a Rountree, R Wes |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Yunfei |e verfasserin |4 aut | |
| 700 | 1 | |a Lewis, Mark G |e verfasserin |4 aut | |
| 700 | 1 | |a Pierson, Theodore C |e verfasserin |4 aut | |
| 700 | 1 | |a Barbosa, Chris |e verfasserin |4 aut | |
| 700 | 1 | |a Tam, Ying |e verfasserin |4 aut | |
| 700 | 1 | |a Shen, Xiaoying |e verfasserin |4 aut | |
| 700 | 1 | |a Ferrari, Guido |e verfasserin |4 aut | |
| 700 | 1 | |a Tomaras, Georgia D |e verfasserin |4 aut | |
| 700 | 1 | |a Montefiori, David C |e verfasserin |4 aut | |
| 700 | 1 | |a Weissman, Drew |e verfasserin |4 aut | |
| 700 | 1 | |a Haynes, Barton F |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t bioRxiv : the preprint server for biology |d 2020 |g (2020) vom: 31. Dez. |w (DE-627)NLM31090014X |7 nnns |
| 773 | 1 | 8 | |g year:2020 |g day:31 |g month:12 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2020.12.30.424745 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2020 |b 31 |c 12 | ||